Skip to main content
. Author manuscript; available in PMC: 2012 Sep 16.
Published in final edited form as: Vaccine. 2011 Jul 27;29(40):7058–7066. doi: 10.1016/j.vaccine.2011.07.028

Figure 4. Breadth and magnitude of HSV-2-specific responses in HSV-2+ subjects.

Figure 4

(A–B) Breadth of the T cell response to HSV-2. The percentage of HSV-2+ subjects who possessed 1 to 8 positive IFNγ ELISPOT responses to the 16 HSV-2 proteins (A) or 1 to 10 positive IFN-γ ELISPOT responses to the 34 HSV-2 peptide pools (B) was determined from all HSV-2+ subjects who possessed HSV-2 peptide-specific responses (n=22). (C) Magnitude of the cumulative T cell response to HSV-2. Shown are cumulative quantitative T cell responses for all subjects (n=2 for HSVneg, n=8 for HSV-1+/2− and n=22 for HSV-2+ subjects) with positive IFN-γ ELISPOT responses to the 34 HSV-2 peptide pools covering 16 HSV-2 proteins.